These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19744964)

  • 1. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes.
    Di Filippo M; Anderson VM; Altmann DR; Swanton JK; Plant GT; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 2010 Feb; 81(2):204-8. PubMed ID: 19744964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
    Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Brownlee WJ; Altmann DR; Alves Da Mota P; Swanton JK; Miszkiel KA; Wheeler-Kingshott CG; Ciccarelli O; Miller DH
    Mult Scler; 2017 Apr; 23(5):665-674. PubMed ID: 27481210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis.
    Zivadinov R; Weinstock-Guttman B; Hashmi K; Abdelrahman N; Stosic M; Dwyer M; Hussein S; Durfee J; Ramanathan M
    Neurology; 2009 Aug; 73(7):504-10. PubMed ID: 19687451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy.
    Stevenson VL; Smith SM; Matthews PM; Miller DH; Thompson AJ
    J Neurol; 2002 Feb; 249(2):171-7. PubMed ID: 11985382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep gray matter volume loss drives disability worsening in multiple sclerosis.
    Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O;
    Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-year, multi-parametric MRI study in patients at presentation with CIS.
    Rocca MA; Agosta F; Sormani MP; Fernando K; Tintorè M; Korteweg T; Tortorella P; Miller DH; Thompson A; Rovira A; Montalban X; Polman C; Barkhof F; Filippi M
    J Neurol; 2008 May; 255(5):683-91. PubMed ID: 18274802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
    Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
    Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
    Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Pichler A; Khalil M; Langkammer C; Pinter D; Bachmaier G; Ropele S; Fuchs S; Enzinger C; Fazekas F
    Mult Scler; 2016 Mar; 22(3):340-6. PubMed ID: 26163072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.
    Jacobsen C; Hagemeier J; Myhr KM; Nyland H; Lode K; Bergsland N; Ramasamy DP; Dalaker TO; Larsen JP; Farbu E; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1109-15. PubMed ID: 24554101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA; Lee JC; Nakamura K; Fisher E
    J Neurol Sci; 2009 Jul; 282(1-2):106-11. PubMed ID: 19100997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial MRI in multiple sclerosis: a prospective pilot study of lesion load, whole brain volume and thalamic atrophy.
    Taylor I; Butzkueven H; Litewka L; MacGregor LR; Szoeke C; Cook M; Mitchell P; Kilpatrick TJ; Tubridy N
    J Clin Neurosci; 2004 Feb; 11(2):153-8. PubMed ID: 14732374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
    Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis.
    Dalton CM; Brex PA; Jenkins R; Fox NC; Miszkiel KA; Crum WR; O'Riordan JI; Plant GT; Thompson AJ; Miller DH
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):141-7. PubMed ID: 12122170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.